Association of norb overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2766-2772

  Kwak, Yee Gyung ^a,b   Truong Bolduc, Que Chi ^a   Kim, Hong Bin ^c   Song, Kyoung Ho ^c   Kim, Eu Suk ^c   Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Inje University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Ciprofloxacin; Efflux pumps; S.aureus

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; GENE MUTATION; GENE OVEREXPRESSION; KOREA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; NORA GENE; NORB GENE; NORC GENE; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS;

CIPROFLOXACIN; EFFLUX PUMPS; S. AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENE EXPRESSION; HOSPITALS; HUMANS; KOREA; MEMBRANE TRANSPORT PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84887549194     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt286     Document Type: Article

References (33)

1. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2: 530-8.
2. Truong-Bolduc QC, Strahilevitz J, Hooper DC. NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1104-7.
3. Yoshida H, Bogaki M, Nakamura S et al. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942-9.
4. Truong-Bolduc QC, Dunman PM, Strahilevitz J et al. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 2005; 187: 2395-405.
5. Costa SS, Falcao C, ViveirosM et al. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol 2011; 11: 241.
6. Blumberg HM, Rimland D, Carroll DJ et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 163: 1279-85.
7. CoronadoVG, Edwards JR, CulverDHet al. Ciprofloxacin resistanceamong nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995; 16: 71-75
8. Harnett N, Brown S, Krishnan C. Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada. Antimicrob Agents Chemother 1991; 35: 1911-3.
9. Flamm RK, Farrell DJ, Mendes RE et al. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis 2012; 74: 54-61.
10. Kim ES, Lee HJ, Chung GT et al. Molecular characterization of methicillin-resistant Staphylococcus aureus isolates in Korea. J Clin Microbiol 2011; 49: 1979-82.
11. Schmitz FJ, Fluit AC, Hafner D et al. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2000; 44: 3229-31.
12. Kim ES, Song JS, Lee HJ et al. A survey of community-associated methicillin-resistant Staphylococcus aureus in Korea. J Antimicrob Chemother 2007; 60: 1108-14.
13. Naimi TS, LeDell KH, Boxrud DJ et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33: 990-6.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI,Wayne, PA, USA, 2009.
15. Schmitz FJ,HofmannB,HansenBet al.Relationshipbetweenciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs andmutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 481-4.
16. Trong HN, Prunier AL, Leclercq R. Hypermutable and fluoroquinoloneresistant clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 2098-101.
17. Truong-Bolduc QC, Hsing LC, Villet R et al. Reduced aeration affects the expression of the NorB efflux pump of Staphylococcus aureus by posttranslational modification of MgrA. J Bacteriol 2012; 194: 1823-34.
18. Kosmidis C, Schindler BD, Jacinto PL et al. Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus. Int J Antimicrob Agents 2012; 40: 204-9.
19. DeMarco CE, Cushing LA, Frempong-Manso E et al. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3235-9.
20. Mathema B, Mediavilla J, Kreiswirth BN. Sequence analysis of the variable number tandem repeat in Staphylococcus aureus protein A gene: spa typing. Methods Mol Biol 2008; 431: 285-305.
21. Strommenger B, Kettlitz C, Weniger T et al. Assignment of Staphylococcus isolates to groups by spa typing, SmaI macrorestriction analysis, and multilocus sequence typing. J Clin Microbiol 2006; 44: 2533-40.
22. Frempong-Manso E, Raygada JL, DeMarco CE et al. Inability of a reserpine-based screen to identify strains overexpressing efflux pump genes in clinical isolates of Staphylococcus aureus. Int J Antimicrob Agents 2009; 33: 360-3.
23. Munoz-Bellido JL, Alonzo MM, Martinez Andres JA et al. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother 1999; 43: 354-6.
24. Ding Y, Onodera Y, Lee JC et al. NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol 2008; 190: 7123-9.
25. Griggs DJ, Marona H, Piddock LJ. Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. J Antimicrob Chemother 2003; 51: 1403-7.
26. Takei M, Fukuda H, Kishii R et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001; 45: 3544-7.
27. Ince D, Zhang X, Hooper DC. Activity of and resistance tomoxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1410-5.
28. Hauschild T, Fessler AT, Billerbeck C et al. Target gene mutations among methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus with elevated MICs of enrofloxacin obtained from diseased food-producing animals or food of animal origin. J Antimicrob Chemother 2012; 67: 1791-3.
29. Schmitz FJ, Fluit AC, Brisse S et al. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 1999; 26: 281-7.
30. Ito H, Yoshida H, Bogaki-ShonaiMet al. Quinolone resistance mutations in theDNAgyrase gyrAandgyrBgenesof Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38: 2014-23.
31. Noguchi N, Okihara T, Namik Yet al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 2005; 25: 374-9.
32. Peck KR, Baek JY, Song JH et al. Comparison of genotypes and enterotoxin genes between Staphylococcus aureus isolates from blood and nasal colonizers in a Korean hospital. J Korean Med Sci 2009; 24: 585-91.
33. Kim T, Yi J, Hong KH et al. Distribution of virulence genes in spa types of methicillin-resistant Staphylococcus aureus isolated from patients in intensive care units. Korean J Lab Med 2011; 31: 30-6.